Clinical efficacy of Kagocel<sup>®</sup> preparation for Treatment of Influenza and ARVI in Children Aged 2 to 6 Years
Blind randomized placebo-controlled study was carried out to estimate the clinical efficacy and safety of Kagocel® preparation in a dose of 1 2 mg <i>[72 </i>mg per course} at influenza and other acute respiratory viral infections in children aged 2 to 6. It was proved that Kagocel<sup>®</sup> is well tolerated by children. The preparation helps shorten the longevity of intoxication symptoms, fever, catarrhal effects in nasopharynx and cardinal symptoms of stenosing laryngotracheitis (bronchitis). The duration of antibiotic therapy and hospital stay is redused. Kagocel® can be recommended for application in pediatric practice for treatment of ARVI and influenza in children older than 2 years.